Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - NOVELION THERAPEUTICS INC. | a17-7729_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 7, 2017
Novelion Therapeutics Inc.
(Exact Name of Registrant as specified in its charter)
|
British Columbia, Canada |
|
000-17082 |
|
N/A |
|
(State or Other Jurisdiction |
|
(Commission |
|
(IRS Employer |
887 Great Northern Way, Suite 250, Vancouver, B.C.
Canada, V5T 4T5
(Address of principal executive offices)
Registrant’s telephone number, including area code: (604) 707-7000
Not Applicable
(Registrant’s name or former address, if change since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On March 7, 2017, Novelion Therapeutics Inc. issued a press release announcing that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office issued its final decision in the inter partes review proceeding initiated by the Coalition for Affordable Drugs VIII, LLC against U.S. Patent Nos. 7,932,268 and 8,618,135 concerning the dosage regimen of JUXTAPID®, affirming the patentability of all claims under such patents. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press Release, dated March 7, 2017. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Novelion Therapeutics Inc. | |
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Gregory D. Perry |
|
|
Name: |
Gregory D. Perry |
|
|
Title: |
Chief Financial and Administrative Officer |
|
|
|
|
|
Date: March 7, 2017 |
|
|